Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist developed for treating type 2 diabetes
Cost barriers She praised Medicares new GLP-1 Bridge Program, which lowers monthly costs for eligible beneficiaries to about $50 if their Part D plans do not already provide coverage
Look at Other Choices : If our coverage aint cutting it, check out options like compounded versions
The study began in December 2023 with estimated completion in May 2026 and is currently actively recruiting across multiple international sites, with Phase 1 healthy volunteer data showing favorable safety profile, dose-proportional pharmacokinetics with 2-week half-life, and approximately 50% reduction in PD-1 expressing CD4+ and CD8+ T cells lasting over 30 days, supporting progression to this Phase 2 efficacy trial (67)
US$ 26.72
US$ 26.02
US$ 25.07
US$ 27.98
US$ 27.35
US$ 21.33
